- Home
- NN vs IBRX Comparison
NN vs IBRX Comparison
Compare NN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NN
- IBRX
- Stock Information
- Founded
- NN 2007
- IBRX 2014
- Country
- NN United States
- IBRX United States
- Employees
- NN N/A
- IBRX N/A
- Industry
- NN Industrial Machinery/Components
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NN Industrials
- IBRX Health Care
- Exchange
- NN Nasdaq
- IBRX Nasdaq
- Market Cap
- NN 2.0B
- IBRX 2.3B
- IPO Year
- NN N/A
- IBRX N/A
- Fundamental
- Price
- NN $14.51
- IBRX $2.55
- Analyst Decision
- NN
- IBRX Strong Buy
- Analyst Count
- NN 0
- IBRX 5
- Target Price
- NN N/A
- IBRX $10.20
- AVG Volume (30 Days)
- NN 1.1M
- IBRX 9.3M
- Earning Date
- NN 08-06-2025
- IBRX 08-05-2025
- Dividend Yield
- NN N/A
- IBRX N/A
- EPS Growth
- NN N/A
- IBRX N/A
- EPS
- NN N/A
- IBRX N/A
- Revenue
- NN $6,259,000.00
- IBRX $56,600,000.00
- Revenue This Year
- NN $18.26
- IBRX $567.98
- Revenue Next Year
- NN $4.59
- IBRX $160.56
- P/E Ratio
- NN N/A
- IBRX N/A
- Revenue Growth
- NN 42.80
- IBRX 4227.22
- 52 Week Low
- NN $6.47
- IBRX $1.83
- 52 Week High
- NN $18.54
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- NN 45.83
- IBRX 47.18
- Support Level
- NN $14.36
- IBRX $2.45
- Resistance Level
- NN $15.17
- IBRX $2.94
- Average True Range (ATR)
- NN 0.72
- IBRX 0.14
- MACD
- NN -0.07
- IBRX 0.02
- Stochastic Oscillator
- NN 44.92
- IBRX 36.07
About NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.